Asia Pacific survey of physicians on asthma and allergic rhinitis (ASPAIR): data from China
10.1097/CM9.0000000000000229
- Author:
David HINDS
1
;
Bhumika AGGARWAL
2
;
Xin DU
3
;
Aruni MULGIRIGAMA
4
;
Sumitra SHANTAKUMAR
5
Author Information
1. Real World Evidence & Epidemiology, GSK, Collegeville, PA 19426-0989, USA
2. Respiratory, Global Classic & Established Products, GSK, 139234 Singapore
3. Respiratory Therapeutic area, GSK, Shanghai 201203, China
4. Respiratory Franchise, GSK, Brentford, Middlesex TW8 9GS, UK
5. Real World Evidence and Epidemiology, GSK, 139234 Singapore
- Publication Type:Journal Article
- Keywords:
Asthma;
Allergic rhinitis;
Coexistent asthma-allergic rhinitis;
China;
Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis;
ASPAIR
- From:
Chinese Medical Journal
2019;132(11):1264-1271
- CountryChina
- Language:English
-
Abstract:
Background:In China, the prevalence of allergic rhinitis (AR) and asthma has increased in the past decade. As these two diseases frequently coexist, the Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR) study aimed to assess physicians’ beliefs and treatment patterns of coexistent asthma-AR across six Asian countries. This analysis presents the results from China.
Methods:The 200 hospital-based general physicians and pediatricians were interviewed from five cities in China. Physicians were questioned in-person about their knowledge, beliefs and management practices for patients with coexistent asthma-AR.
Results:Approximately 70% of the physicians interviewed routinely evaluated their patients with asthma or AR for signs of coexistent disease. While the majority of physicians (>90% of physicians) recognized the increased burden of coexistent asthma-AR vs. one condition alone and that coexistent disease requires additional treatment, most physicians (96%) also believed that patients with coexistent asthma-AR were well managed if either condition alone improved. Similarly, although 71% of physicians selected a combination of intranasal and inhaled corticosteroids as their preferred treatment for coexistent asthma-AR, in line with treatment guidelines, two fifths of physicians indicated that treatment for coexistent disease requires too much medication and that their patients prefer oral medications and a third of physicians believed that corticosteroids should be delayed in children.
Conclusions:This survey demonstrates that physicians interviewed in China have a broad understanding of coexistent asthma-AR and its impact on patients. A holistic approach to patient management with informed decisions regarding patients’ overall treatment will benefit patients who suffer from coexistent disease.
